Abstract 527P
Background
Leptomeningeal metastases (LM) of lung cancer represent a severe neurological complication with a poor prognosis and limited effective treatments. Although intraventricular chemotherapy (IVC) is the preferred management for LM, there is currently insufficient data to support its effectiveness.
Methods
We conducted a retrospective study that analyzed data from consecutive patients with LM from lung adenocarcinoma who underwent Ommaya reservoir insertion at the Nanjing Chest Hospital between 2020 and 2022. The diagnosis of LM was based on either cerebrospinal fluid (CSF) cytology or concordant clinical and neuroimaging findings. The chemotherapy regimen consisted of pemetrexed (30mg or 50mg) and dexamethasone (5mg) administered twice a week for up to 2 weeks during the induction phase, followed by a maintenance phase once a month until progression or maximal doses were reached.
Results
We retrospectively analyzed 56 patients (median age, 56 years) with driver gene mutations, including 46 patients with EGFR mutations, 2 patients with other gene mutations, and 8 patients with non-driver genes. Of the patients, 48.3% had an ECOG PS of 4, 35.7% had an ECOG PS of 3, and 16% had an ECOG PS of 2. Additionally, 41 patients (73.2%) received a 30mg dose of pemetrexed, and 15 patients (26.8%) received a 50mg dose. In all patients, 31 had a response, 19 had stable disease (SD), and 6 had disease progression (PD), resulting in an overall response rate (ORR) of 55.4% and a disease control rate (DCR) of 89.3%. The median progression-free survival (mPFS) was 6.8 months, and the median overall survival (mOS) was not reached. Subgroup analysis showed that the mPFS for the pemetrexed 50mg and 30mg groups was 12 months and 6.8 months, respectively (p=0.006), and the mPFS was 9.6 months versus 4 months in the ECOG PS of 2-3 and 4 arms(Fig1B), respectively (p=0.001). The overall adverse event (AE) rate was 65%, with all adverse effects, including nausea, vomiting, seizures, and myelosuppression, being mild and transient.
Conclusions
In this real-world study, IVC with pemetrexed demonstrated excellent and encouraging results in patients with lung adenocarcinoma and LM, at an acceptable cost of toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract